New Frontier for Overseas Business

On May 26, Zhuhai Trinomab Biopharmaceutical Co., Ltd. (hereinafter referred to as "Trinomab") and Shanghai Pharma International Business Division (Shanghai Pharma Import & Export Co., Ltd.) held a signing ceremony in Shanghai for their strategic commercialization cooperation on Siltartoxatug Injection in the Philippines. Zheng Weihong, Vice Chairman and General Manager of Zhuhai Trinomab Biopharmaceutical Co., Ltd., and Yan Jun, General Manager of Shanghai Pharma International Business Division (Shanghai Pharma Import & Export Co., Ltd.), attended the ceremony, with relevant business teams from both parties participating in the event.

(The signing ceremony for the strategic commercialization cooperation of Siltartoxatug Injection in the Philippines)

Siltartoxatug Injection is the world's first recombinant monoclonal antibody drug against tetanus toxin independently developed by Trinomab, and a significant innovation in the field of emergency tetanus prevention. The product was approved for launch in China in 2025 and has been included in evidence-based recommendations such as the latest "Expert Consensus on the Application of Passive Immunization Agents for Tetanus Post-Exposure Prophylaxis" and "Expert Consensus on the Clinical Application of Recombinant Monoclonal Antibody Against Tetanus Toxin", providing a safer, more convenient, and more stable innovative solution for emergency tetanus prevention in adults. This cooperation is a key implementation project of Trinomab's international business, marking a crucial step in the company's overseas regional expansion. It will enable Siltartoxatug Injection to benefit more tetanus-exposed patients in Southeast Asia and even globally, opening a new stage of serving global health with innovative drugs and achieving the leap from "China's New Innovation" to "Global New Innovation".

In the future, taking this signing as an opportunity, both parties will leverage their respective strengths in innovative drug R&D, production quality, regulatory support, overseas market access, and localized commercial operations to jointly advance the regulatory filing and commercialization implementation of Siltartoxatug Injection in the Philippine market, providing more high-quality and accessible treatment options for local patients.

This strategic cooperation is not only an important achievement of the two parties in deepening cooperation in the Southeast Asian market, but also lays a solid foundation for Trinomab to further promote the international commercial cooperation of innovative drugs. Both parties will continue to strengthen communication and collaboration, explore more opportunities for international cooperation in terms of more products, more regions, and deeper levels, and jointly help Chinese innovative drugs go global.

About Shanghai Pharma International Business Division (Shanghai Pharma Import & Export Co., Ltd.)

Shanghai Pharma International Business Division is a key carrier of Shanghai Pharma's international business, possessing capabilities in overseas registration and localized commercial operations. Relying on the industrial resources of Shanghai Pharma Group, the company continues to deepen market development in key regions such as Southeast Asia and the Middle East & North Africa, actively promoting the internationalization of high-quality Chinese drugs and innovative products.

About Zhuhai Trinomab Biopharmaceutical Co., Ltd.

Zhuhai Trinomab Biopharmaceutical Co., Ltd. is a global innovative biopharmaceutical company focusing on the R&D of original fully human monoclonal antibody drugs. The company's core technology is the next-generation "High-Throughput Fully Human Monoclonal Antibody R&D Comprehensive Technology Platform HitmAb", and it is committed to developing fully human monoclonal antibody drugs with independent intellectual property rights, high differentiation, and high efficacy, so as to improve existing medical measures for the prevention and treatment of infectious diseases, autoimmune diseases, malignant tumors, and other diseases. The Next-Gen "Tetanus Shot" Siltartoxatug Injection independently developed based on this platform was approved for launch in China in February 2025. In December of the same year, the drug was successfully included in the National Reimbursement Drug List (NRDL) and has been uniformly implemented nationwide since January 1, 2026.